Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Non-Thermal Plasma Used During Surgery to Help Prevent Recurrent Chronic Subdural Hematoma

Official title: Application of Non-Thermal Plasma in the Surgical Bed of Chronic Subdural Hematoma to Reduce the Post-Drainage Recurrence Rate: A Randomized Controlled Trial

Run by National Institute of Nuclear Research - Mexico · NCT07656818 · Data updated 2026-11-12

A randomized trial tests whether applying non-thermal plasma during standard surgery to drain a chronic subdural hematoma can reduce recurrence within 6 months.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorNational Institute of Nuclear Research - Mexico
Academic / other
Locations1 site (Ocoyoacac, State of Mexico)
StatusRecruiting
StartedMarch 2, 2026
Main results expectedFebruary 28, 2027
Study endsApril 30, 2027
Registry record updatedJune 18, 2026
Trial IDNCT07656818 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 years and older with symptomatic cSDH requiring surgical drainage and able to provide consent.

Probably not a fit

Patients with non-symptomatic hematomas, non-communicating subdural conditions, or contraindications to surgery or NTP may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, randomized, parallel-group study compares standard surgical drainage to the same surgery with intraoperative non-thermal plasma (NTP) application. Patients with symptomatic chronic subdural hematoma needing drainage are assigned 1:1 to receive NTP on exposed dura, residual membrane, and surrounding tissues, or no NTP. The trial includes CT and clinical follow-ups at 1 week, 3 months, and 6 months to assess recurrence, safety, and functional outcomes. It is conducted at ISSEMYM Medical Centre Toluca (with ININ collaboration) to explore whether NTP can modulate the subdural environment and reduce recurrent hematoma.

Why it matters

Potential benefit: If successful, NTP could lower the chance of recurrence after surgery and improve recovery.

How similar studies have gone: Preclinical and early clinical work suggest anti-inflammatory and regenerative effects of NTP in similar contexts, but this specific application is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults ≥ 18 years of age
* Diagnosis of symptomatic chronic subdural hematoma (cSDH) requiring surgical drainage (burr hole drainage or craniotomy)
* Ability to provide written informed consent (or consent from legal representative if patient is incapacitated)

Exclusion Criteria:

* Pure acute or subacute subdural hematoma
* Uncontrolled coagulopathy or bleeding disorder
* History of intracranial aneurysm or prior cerebrovascular event with residual deficit
* Presence of active intracranial metallic implants or electronic devices (e.g., programmable shunt, cardiac pacemaker, deep brain stimulator) in the head region
* Pregnancy or lactation
* Participation in another interventional clinical trial within 30 days prior to screening

Where it's running

  • Plasma Physics Laboratory, National Institute of Nuclear Research
    Ocoyoacac, State of Mexico, Mexico
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.